Novo Nordisk A/S
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products i… Read more
Market Cap & Net Worth: Novo Nordisk A/S (NONOF)
Novo Nordisk A/S (PINK:NONOF) has a market capitalization of $209.48 Billion ($209.48 Billion) as of March 18, 2026. Listed on the PINK stock exchange, this USA-based company holds position #95 globally and #75 in its home market, demonstrating a -13.05% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Novo Nordisk A/S's stock price $62.16 by its total outstanding shares 3369988201 (3.37 Billion).
Novo Nordisk A/S Market Cap History: 2015 to 2025
Novo Nordisk A/S's market capitalization history from 2015 to 2025. Data shows growth from $66.21 Billion to $209.48 Billion (13.08% CAGR).
Novo Nordisk A/S Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Novo Nordisk A/S's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.68x
Novo Nordisk A/S's market cap is 0.68 times its annual revenue
0.84x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
2.05x
Novo Nordisk A/S's market cap is 2.05 times its annual earnings
11.15x
Lower than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $42.38 Billion | $111.78 Billion | $37.92 Billion | 0.38x | 1.12x |
| 2017 | $64.95 Billion | $111.70 Billion | $38.13 Billion | 0.58x | 1.70x |
| 2018 | $56.88 Billion | $111.83 Billion | $38.63 Billion | 0.51x | 1.47x |
| 2019 | $74.47 Billion | $122.02 Billion | $38.95 Billion | 0.61x | 1.91x |
| 2020 | $105.57 Billion | $126.95 Billion | $42.14 Billion | 0.83x | 2.51x |
| 2021 | $166.62 Billion | $140.80 Billion | $47.76 Billion | 1.18x | 3.49x |
| 2022 | $224.64 Billion | $176.95 Billion | $55.52 Billion | 1.27x | 4.05x |
| 2023 | $341.63 Billion | $232.26 Billion | $83.68 Billion | 1.47x | 4.08x |
| 2024 | $360.00 Billion | $290.40 Billion | $100.99 Billion | 1.24x | 3.56x |
| 2025 | $209.48 Billion | $308.36 Billion | $102.20 Billion | 0.68x | 2.05x |
Competitor Companies of NONOF by Market Capitalization
Companies near Novo Nordisk A/S in the global market cap rankings as of March 18, 2026.
Key companies related to Novo Nordisk A/S by market ranking:
- Eli Lilly and Company (NYSE:LLY): Ranked #15 globally with a market cap of $883.37 Billion USD.
- Johnson & Johnson (NYSE:JNJ): Ranked #18 globally with a market cap of $574.95 Billion USD.
- AbbVie Inc (NYSE:ABBV): Ranked #29 globally with a market cap of $390.88 Billion USD.
- AstraZeneca PLC (NASDAQ:AZN): Ranked #46 globally with a market cap of $296.35 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #15 | Eli Lilly and Company | NYSE:LLY | $883.37 Billion | $989.12 |
| #18 | Johnson & Johnson | NYSE:JNJ | $574.95 Billion | $243.19 |
| #29 | AbbVie Inc | NYSE:ABBV | $390.88 Billion | $221.45 |
| #46 | AstraZeneca PLC | NASDAQ:AZN | $296.35 Billion | $192.01 |
Novo Nordisk A/S Historical Marketcap From 2015 to 2025
Between 2015 and today, Novo Nordisk A/S's market cap moved from $66.21 Billion to $ 209.48 Billion, with a yearly change of 13.08%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $209.48 Billion | -41.81% |
| 2024 | $360.00 Billion | +5.38% |
| 2023 | $341.63 Billion | +52.08% |
| 2022 | $224.64 Billion | +34.82% |
| 2021 | $166.62 Billion | +57.83% |
| 2020 | $105.57 Billion | +41.77% |
| 2019 | $74.47 Billion | +30.92% |
| 2018 | $56.88 Billion | -12.42% |
| 2017 | $64.95 Billion | +53.27% |
| 2016 | $42.38 Billion | -36.00% |
| 2015 | $66.21 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 17th, 2026 the market cap of Novo Nordisk A/S was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $209.48 Billion USD |
| MoneyControl | $209.48 Billion USD |
| MarketWatch | $209.48 Billion USD |
| marketcap.company | $209.48 Billion USD |
| Reuters | $209.48 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.